Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current study was undertaken to assess baseline and on-treat...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Immunother Cancer
Κύριοι συγγραφείς: Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J, Sharfman, William H, Kudchadkar, Ragini R, Brohl, Andrew S, Friedlander, Philip A, Daud, Adil, Kluger, Harriet M, Reddy, Sunil A, Boulmay, Brian C, Riker, Adam, Burgess, Melissa A, Hanks, Brent A, Olencki, Thomas, Kendra, Kari, Church, Candice, Akaike, Tomoko, Ramchurren, Nirasha, Shinohara, Michi M, Salim, Bob, Taube, Janis M, Jensen, Erin, Kalabis, Mizuho, Fling, Steven P, Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A, Topalian, Suzanne L
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: BMJ Publishing Group 2021
Θέματα:
Clinical/Translational Cancer Immunotherapy
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8061836/
https://ncbi.nlm.nih.gov/pubmed/33879601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002478
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια